赛特科科技

CYTR NASDAQ
0.5579
-0.0071
-1.26%
盘后: 0.5579 0 0.00% 16:57 05/23 EDT
开盘
0.5500
昨收
0.5650
最高
0.5800
最低
0.5402
成交量
9.09万
成交均量(3M)
17.18万
52周最高
1.370
52周最低
0.3300
换手率
0.27%
市值
1,876.64万
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供赛特科科技 CYTR股票价格,赛特科科技股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
展开 >

最近浏览

名称
价格
涨跌幅